Eric Easom

Mr. Easom has over 29 years of leadership experience in the biotechnology and pharmaceutical industry and has spent the last 15 years focused on bringing innovation to address significant unmet needs in infectious diseases, focused on the developing world. In addition to being the Founder, President and CEO of AN2 Therapeutics, Mr. Easom also serves on the Board of Directors for the Chagas Disease Foundation, Resilient Biotics, and is an advisor for the California Life Sciences Institute. Previously, Mr. Easom spent 9 years at Anacor Pharmaceuticals, which was acquired by Pfizer. During his tenure, he led Anacor’s R&D on neglected disease programs that achieved global prominence, working in close partnership with the Bill and Melinda Gates Foundation, the Wellcome Trust, The University of Georgia (Tarleton Lab), Medicines for Malaria Venture, Global Alliance for Veterinary Medicine, Drugs for Neglected Disease initiative (DNDi), GlaxoSmithKline (GSK), Eli Lilly & Company, the University of California, San Francisco (Rosenthal, McKerrow, and Sakanari Labs), Colorado State University (Slayden and Lenaerts’ Labs), DTRA, Walter Reed, the London School of Hygiene and Tropical Medicine (Croft Lab), TB Alliance, the global Anti-Wolbachia Consortium, and numerous other partners. The Anacor Neglected Diseases team raised over $80M in funding and discovered over a dozen potentially transformational medicines for diseases such as malaria, tuberculosis, river blindness, cryptosporidiosis and trypanosome diseases including Chagas disease, African sleeping sickness, and leishmaniasis. Mr. Easom also served on the Board of Directors for the Infectious Disease Research Institute, from 2007-2014, serving as Chairman from 2009-2013. The majority of his early career was at Eli Lilly and Company, followed by McKesson and other biotechnology companies such as MedImmune and InteKrin Therapeutics. Mr. Easom earned a BS and Masters in Electrical Engineering from the University of Louisville, and an MBA from Indiana University, Kelley School of Business.